The effect of the TIM-3 blockade on tumor tissue is preferential.131,156 Therefore, targeting TIM-3 in a person with neck cancer will only affect other tissues if those tissues have some known ligands of the TIM-3 blockade.157 TIM-3 blockade is regulated by functional specification, a concept through which pathways such as the TIM-3 pathway sometimes regulate immune responses’ distinct features; thus, some other tissues in a patient with the neck cancer can remain unaffected by the targeting.134,156,157. The gene discussed is HAVCR2; the disease is malignant tumor of neck.